Skip to main content

Japanese health ministry panel recommends approval of Alzheimer's treatment Leqembi

A panel convened by Japan's health ministry made a recommendation Monday in favor of endorsing the Alzheimer's disease medication Leqembi.

A Japanese health ministry panel on Monday recommended approval of the Alzheimer's disease treatment Leqembi, following standard approval for the drug granted by U.S. regulators last month.

REVANCE'S BOTOX RIVAL GETS FDA APPROVAL FOR PAINFUL NECK MUSCLE CONDITION

The expert panel's decision sets the stage for official approval of the drug, co-developed by Japan's Eisai and U.S.-based Biogen.

An Eisai executive said this month the company expects to begin marketing Leqembi in Japan within about 60 days of receiving insurance reimbursement approval from the country's national health system.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.